Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022
Subscribe To Our Newsletter & Stay Updated